The estimated Net Worth of Peter M Allen is at least $4.79 Million dollars as of 6 July 2015. Peter Allen owns over 30,494 units of Haemonetics stock worth over $4,679,980 and over the last 21 years Peter sold HAE stock worth over $111,505.
Peter has made over 41 trades of the Haemonetics stock since 2003, according to the Form 4 filled with the SEC. Most recently Peter exercised 30,494 units of HAE stock worth $831,876 on 6 July 2015.
The largest trade Peter's ever made was exercising 53,288 units of Haemonetics stock on 4 January 2013 worth over $1,092,937. On average, Peter trades about 4,701 units every 72 days since 2003. As of 6 July 2015 Peter still owns at least 64,596 units of Haemonetics stock.
You can see the complete history of Peter Allen stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, and Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: